Osporil (Zoledronic Acid)

Zoledronic Acid, the active ingredient in Osporil, is a bisphosphonate presented as a 5 mg/5 ml solution for intravenous use. It treats osteoporosis and bone loss conditions in post‑menopausal women and men at risk of fracture. GNH USA supplies Osporil as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, and pharmacies worldwide.

GNH USA supplies Osporil as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, and pharmacies worldwide.

Osporil is a bisphosphonate that acts on bone metabolism to reduce skeletal-related events.

- Osteoporosis: reduces fracture risk in post‑menopausal women and men with low bone density. - Paget’s disease of bone: normalises abnormal bone remodeling. - Bone metastases from solid tumours: lowers incidence of skeletal‑related complications. - Hypercalcaemia of malignancy: helps lower elevated calcium levels. - Primary hyperparathyroidism (pre‑surgical): prepares for surgical intervention. - Chronic renal failure with secondary osteodystrophy (only where approved).